Merck Buys Maker of HIF2α Inhibitor.
Merck's acquisition of Peloton Therapeutics gives it access to a novel inhibitor of a protein that enables cancer cells to survive hypoxia. The drug blocks the HIF2α transcription factor and is being tested in a phase I/II trial for clear cell renal cell carcinoma. A phase II trial is testing a related Peloton compound in glioblastoma.